OLN heads into its October 29 earnings date with a sharp contradiction: short sellers added aggressively to positions this week while options traders moved in the opposite direction, cutting put exposure to its lowest level in months.
The short interest story is the week's headline. Bearish positioning jumped 15.6% over the past seven days, bringing SI to 11.7% of the free float, roughly 13.4 million shares. That follows a more gradual build through most of September, with the bulk of the weekly increase arriving in a single step between September 22 and September 24. The ORTEX short score has climbed to 55, up from around 51 at the start of the month, and has moved higher every session this week. Yet the borrow market gives no indication of a squeeze setup: availability is ample at roughly 801% of current short interest, meaning there are eight shares available to borrow for every one already out on loan. Cost to borrow is just 0.51%, up 37% over the month in absolute terms but still well within the low range. The borrow side of this is not under stress; what is under stress is the stock price itself, down 8.3% on the week and 10% over the past month, closing Tuesday at $15.43.
Options positioning complicates the picture. The put/call ratio dropped to 0.58, more than two standard deviations below its 20-day average of 0.68, and near the lower end of the past 52 weeks. Call volume is running well above put volume, the mirror image of what you would expect alongside a short-interest surge of this magnitude. One plausible read is that the call activity reflects short sellers buying upside protection or other traders positioning for a bounce from what are multi-year lows. The stock's RSI was flagged at 33.7 in a recent note, deep into oversold territory.
The Street has spent most of the past two months cutting targets. Goldman Sachs, Wells Fargo, UBS, RBC, and Truist all trimmed in early August after weak results. Wells Fargo also downgraded to Equal-Weight. The consensus has landed around Neutral, with a mean target of $21.13, implying roughly 37% upside from current levels. Citigroup, reinstated at Neutral in mid-September with a $19 target, trimmed that to $17 on September 30, the most recent move on record. Keybanc is the lone constructive voice on the Street, initiating at Overweight with a $26 target on September 11. Valuation multiples reflect the damage: P/B has compressed 13% over the past 30 days to just above 1x book, and EV/EBITDA is at 6.6x. The EPS surprise factor score sits at just the 5th percentile, a poor track record on beats, though 30-day EPS momentum has moved to the 96th percentile, suggesting recent estimate revisions have turned more positive. The bear case centres on a heavy 2026 turnaround schedule and a "value over volume" commercial model for the chlor-alkali business that will take years to optimise. Bulls point to caustic soda pricing in North America and ammunition demand, but both have been slow to move the needle.
On ownership, the most notable 13D/G register entry is Hotchkis and Wiley, which disclosed a 13.39% stake in February 2026, up from 10.2% previously, making it the largest disclosed concentrated holder on the register. AQR Capital also crossed the 5% threshold and filed a 13G in August 2026. No 13D activist filing has been made against OLN. As the ORTEX disclosure note flags, 13D/G positions are event-driven around the 5% threshold, and holders who fall below that level may not file again. BlackRock added around 497,000 shares as of August 31, and Dimensional Fund Advisors added 538,000 over the same period, modest incremental buying from passive and quantitative managers. The insider register is stale, with the last filed Form 4 transactions dating to mid-June, all routine option exercises and tax withholding transactions carrying no open-market buying signal.
The recent earnings history adds context worth holding in mind. After the July 30 results, OLN fell roughly 16% on the day and held those losses over the following week. The prior print, in late August, produced a negligible 1-day move. Peer pressure is broadly negative this week: HUN lost 7.4% on the week, and TROX dropped 9.3%, suggesting sector-wide chemical weakness is amplifying OLN's move rather than stock-specific deterioration alone.
With 29 days to the October 29 print, the question sharpening around OLN is whether a second consecutive weak quarter will finally force more concentrated holders to reassess, or whether the gap between the $15.43 price and the Street's $21 consensus begins to attract fresh buying into a deeply depressed name.
See the live data behind this article on ORTEX.
Open OLN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
